IRD · Opus Genetics, Inc.

This financing represents a significant new debt obligation for Opus Genetics, materially altering its capital structure and balance sheet risk profile. The $35 million initial tranche provides near-term liquidity but anchors a much larger $155 million facility—$105 million of which is contractually committed—subject to milestone achievement and customary closing conditions. The floating-rate structure, tied to Term SOFR with a floor, exposes the company to rising interest expense if benchmark rates increase, while quarterly payments impose predictable near-term cash outflows. Crucially, the Notes are secured by substantially all assets of the Company and its subsidiaries and backed by subsidiary guarantees, meaning default could trigger broad asset liquidation and impair future financing flexibility. The 2033 maturity offers long-dated runway, but the inclusion of acceleration triggers for material adverse events—broadly defined in such agreements—introduces refinancing and operational uncertainty, particularly for a clinical-stage biotechnology company where pipeline progress directly influences financial viability. Investors should assess the use of proceeds (not disclosed here), the likelihood of drawing the remaining $50 million uncommitted tranche, and how this leverage aligns with anticipated cash burn and value inflection points from ongoing development programs.